80125-14-0
80125-14-0 structure
- Name: Remoxipride
- Chemical Name: 3-bromo-N-[[(2S)-1-ethylpyrrolidin-2-yl]methyl]-2,6-dimethoxybenzamide
- CAS Number: 80125-14-0
- Molecular Formula: C16H23BrN2O3
- Molecular Weight: 371.26900
- Catalog: Signaling Pathways GPCR/G Protein Dopamine Receptor
- Create Date: 2018-03-07 08:00:00
- Modify Date: 2024-01-02 19:57:23
-
(S)-Remoxipride ((-)-Remoxipride) is a selective dopamine D2-receptor antagonist with an IC50 value of 1.57 μM. (S)-Remoxipride can be used for the research of psychotic disorder[1].
| Name | 3-bromo-N-[[(2S)-1-ethylpyrrolidin-2-yl]methyl]-2,6-dimethoxybenzamide |
|---|---|
| Synonyms |
Remoxipridum [INN-Latin]
(S)-remoxipride (S)-3-bromo-N-[(1-ethylpyrrolidin-2-yl)methyl]-2,6-dimethoxybenzamide Remoxiprida (-)-N-ethyl-2-(3-bromo-2,6-dimethoxybenzamidomethyl)pyrrolidine remoxipiride S(-)-3-bromo-N-[(1-ethyl-2-pyrrolidinyl)methyl]-2,6-dimethoxy-benzamide remoxipride FLA-731 Romoxipride Roxiam Remoxipride [USAN:BAN:INN] Remoxiprida [INN-Spanish] Remoxipridum MFCD00869705 |
| Description | (S)-Remoxipride ((-)-Remoxipride) is a selective dopamine D2-receptor antagonist with an IC50 value of 1.57 μM. (S)-Remoxipride can be used for the research of psychotic disorder[1]. |
|---|---|
| Related Catalog | |
| Target |
D2 Receptor:1.57 μM (IC50) D1 Receptor:＞100 μM (IC50) α1-Adrenoccptor:42 μM (IC50) |
| In Vitro | (S)-Remoxipride (1-100 μM; 20 min) shows binding efficiency with IC50s of ＞100, 1.57 and 42 μM for dopamine D1, dopamine D2 and α1-Adrenoccptor, respectively[1]. |
| In Vivo | (S)-Remoxipride (0.1-100 μM/kg; i.p. 60 min prior to apomorphine) blockades apomorphine-induced behaviors s in rats and vomiting in dogs[1]. (S)-Remoxipride (0.1-10 mg/kg; i.p. 30 min prior to apomorphine) displaces [3H]spiperone from both striatal and extra-striatal areas[1]. Animal Model: Male Sprague-Dawley rats[1] Dosage: 0.1-100 μM/kg Administration: Intraperitoneal injection; 0.1-100 μM/kg; 60 min prior to apomorphine Result: Blocked apomorphine-induced hyperactivity and dose-dependent blockaded apomorphine-induced behaviors in vivo. Animal Model: Male and female beagle dogs[1] Dosage: 0.25-5 μM/kg Administration: Oral gavage; 0.25-5 μM/kg; 60 min prior to apomorphine Result: Blocked apomorphine-induced vomiting in dogs. |
| Density | 1.292 |
|---|---|
| Boiling Point | 439.9ºC at 760 mmHg |
| Molecular Formula | C16H23BrN2O3 |
| Molecular Weight | 371.26900 |
| Flash Point | 219.8ºC |
| Exact Mass | 370.08900 |
| PSA | 50.80000 |
| LogP | 3.00920 |
| Index of Refraction | 1.54 |
CHEMICAL IDENTIFICATION
HEALTH HAZARD DATAACUTE TOXICITY DATA
|
| Hazard Codes | Xi |
|---|---|
| Risk Phrases | R36/37/38:Irritating to eyes, respiratory system and skin . |
| Safety Phrases | S26-S36-S24/25 |
| WGK Germany | 3 |
|
~%
80125-14-0 |
| Literature: Journal of Medicinal Chemistry, , vol. 25, # 11 p. 1280 - 1286 |
|
~%
80125-14-0 |
| Literature: Journal of Medicinal Chemistry, , vol. 25, # 11 p. 1280 - 1286 |
|
~%
80125-14-0 |
| Literature: Journal of Medicinal Chemistry, , vol. 25, # 11 p. 1280 - 1286 |
|
~%
80125-14-0 |
| Literature: Medicinal Chemistry Research, , vol. 6, # 2 p. 69 - 80 |
| Precursor 5 | |
|---|---|
| DownStream 0 | |